calendar
2,363 catalysts · 4,686 phase readout · 2,344 8k filing · 285 earnings · 172 phase 2 completion · 163 pdufa · 73 phase 1 completion
next 91 dayslessmore
MonWedFri
2,363 catalysts · 4,686 phase readout · 2,344 8k filing · 285 earnings · 172 phase 2 completion · 163 pdufa · 73 phase 1 completion
Items: 7.01, 9.01
Items: 5.02, 7.01, 9.01
Items: 1.01, 8.01, 9.01
Items: 7.01, 8.01, 9.01
Items: 5.02, 9.01
Items: 5.02, 9.01
Items: 1.02
Items: 8.01
Items: 8.01
Items: 2.02, 7.01, 9.01
Items: 5.02
Items: 5.02, 5.07, 9.01
Items: 7.01, 8.01, 9.01
Items: 5.02, 7.01, 9.01
Items: 2.02, 9.01
Items: 8.01
Items: 7.01, 9.01
Items: 1.01, 7.01, 8.01, 9.01
Items: 5.02, 7.01, 9.01
Items: 7.01, 9.01
Items: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
Therapy area: Infectious Disease, Respiratory. Indication: Asthma, Influenzavirus A Infections, Influenzavirus B Infections
Therapy area: Gastrointestinal, Infectious Disease, Oncology. Indication: Acral Lentiginous Melanoma, Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Anaplastic Thyroid Cancer, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Breast Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma (cSCC), Endometrial Cancer, Ependymoma, Epithelial Ovarian Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Ewing S
Items: 1.01, 7.01, 9.01
Items: 1.01, 9.01
Items: 3.01
Items: 5.02
Items: 8.01, 9.01
Items: 5.02, 9.01
Items: 1.01, 2.03, 9.01
Items: 5.02, 9.01
Items: 1.01, 3.01, 9.01
Items: 8.01, 9.01
Items: 5.02
Items: 5.02, 9.01
Items: 1.01, 8.01, 9.01
Items: 5.02
Items: 5.02
Items: 1.01, 2.01, 3.02, 9.01
Items: 9.01
Items: 5.07
Items: 1.01, 8.01, 9.01
Items: 1.01, 3.02, 9.01
Items: 1.01, 9.01
Items: 5.03, 9.01
Items: 1.01, 9.01
Items: 5.02, 9.01
Items: 2.03
Items: 7.01, 8.01, 9.01
Items: 2.04